Avient Corporation’s Post

What is the Wheeler Difference? Wheeler Bio, Inc. is bringing a new paradigm to biomanufacturing through our commitment to an open-source, transparent, and predictable service platform made possible by our strong partnership culture. By collaborating with pioneering technology providers and integrating with discovery CROs, we provide our clients with access to the most advanced and effective biomanufacturing solutions while reducing risk and improving efficiency. Collaboration is at the core of the Wheeler model as we believe the only way to build genuine trust is through open communication, unwavering integrity, and consistent results. Let's discuss! In your experience, what are the key factors in building trust with your partners? Let us know in the comments. Explore the Wheeler difference: https://lnkd.in/gAbvMwu5 #pharma #pharmaindustry #biopharma #biotech

🤖 Curious about AI in Bioprocessing? Beate Hadeball, PhD and Andreas Dorn are your go-to duo! They're armed with insights on our Solentim ecosystem and are ready to embark on a tech journey with you! See you at #Festivalofbiologics #AdvancedInstruments

When it comes to getting the most from your lab and manufacturing facilities, it’s important for life sciences companies to take a proactive approach. Read JLL’s five ways to increase efficiency and set the stage for innovation. #JLL #LifeScience #Innovation

Can #biopharma’s drug-focused R&D strategy remain profitable? Or does it require adaptation? Philipp Steinbach and Dr. Kerstin Bode-Greuel from Bioscience Valuation answer these exciting questions in their latest article on Plattform Life Sciences. Continue reading: https://lnkd.in/e3RzEd5h #biotechnology #researchanddevelopment #pharmacy #profit

Proud of the work Clarivate Life Sciences & Healthcare does to improve patient lives 😌 The modern brand landscape is evolving fast. Brands, whether new or heritage, are operating in a world where consumer preferences and purchasing behavior are dynamic, even unpredictable. Amidst these challenges, resourceful new brands are cutting through the noise. In Top 100 New Brands™ 2023, we identify the new brands that are navigating these challenges ...

Being a leader in biologic manufacturing means believing in transformational technology to change the dynamics; investing in expertise, science and technology to drive down cost, time, deliver quality so our mission can be delivered: expand global access to biotherapeutics. Our integrated continuous manufacturing platforms operate within cGMP facilities that employ autonomous clean room technology for the cost-efficient production of antibodies, next-generation biologics and biosimilar products.#researchneverstops #antibodies #science #technology #biologics #JCHO Read the attached and Ask us how we can help your organization deliver to your mission. #patientsarewaiting

Our colleague at Kymanox recently published an article in Life Science Leader. In this article, Fran DeGrazio outlines the importance of material selection for medical products: "In 2021, 36% of medical device failures reported to the US FDA were materials related thus emphasizing the importance of ensuring materials are appropriately selected." Read her article, "Living In A Material World The Importance Of Understanding Materials In Medical Product Development" here: https://lnkd.in/gxrV68tY #pharmaindustry #LifeSciences #medicaldevice

OVERCOME KEY mAbs FORMULATION OBSTACLES Harnessing Amino Acid Derivatives for Enhanced Viscosity Reduction and Stability of mAbs | Avantor (avantorsciences.com) Most monoclonal antibodies (mAbs) are developed with low protein concentrations, and typically delivered to the patient in liquid form via injection or intravenous infusion (IV). However, there are a growing number of indications that prefer intramuscular or subcutaneous injections - mainly so that a patient can self-administer the drug at home and reduce hospital stays and/or treatment costs, increasing patient compliance. While drugs delivered subcutaneously have significant patient benefits, they add additional manufacturing challenges - mainly due to pain and pressure at the injection site when volumes exceed 1 - 2 ml. This limited volume means that mAbs must be formulated in higher concentrations to administer an efficacious dose to the patient. Higher concentrations create high viscosity, and can also create undesirable protein-protein attractive interactions that leads to protein aggregation. This article summarizes our research to identify novel excipients that not only reduce viscosity of high-concentration formulation but also improve stability across a wide concentration range.

Thoughts on this? >> Takeda’s new deal with Kumquat; IL-2 biotech raises $55M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #pharmaceutical #healthcare

Thoughts on this? >> Takeda’s new deal with Kumquat; IL-2 biotech raises $55M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #biotech #healthcare